Amgen Inc. (NASDAQ: AMGN) Stock Competitors & Peer Comparison

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while LLY trades at $1,183.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas LLY's P/E ratio is 37.59. In terms of profitability, AMGN's ROE is +0.89%, compared to LLY's ROE of +0.93%. Regarding short-term risk, AMGN is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check LLY's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, JNJ has a market cap of 653.6B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while JNJ trades at $271.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas JNJ's P/E ratio is 25.28. In terms of profitability, AMGN's ROE is +0.89%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, AMGN is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check JNJ's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, ABBV has a market cap of 466.9B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while ABBV trades at $264.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas ABBV's P/E ratio is 25.93. In terms of profitability, AMGN's ROE is +0.89%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, AMGN is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check ABBV's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, MRK has a market cap of 367.4B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while MRK trades at $148.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas MRK's P/E ratio is 46.34. In terms of profitability, AMGN's ROE is +0.89%, compared to MRK's ROE of +0.07%. Regarding short-term risk, AMGN is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check MRK's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, NVS has a market cap of 276.5B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while NVS trades at $145.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas NVS's P/E ratio is 16.74. In terms of profitability, AMGN's ROE is +0.89%, compared to NVS's ROE of +0.30%. Regarding short-term risk, AMGN is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check NVS's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, AZN has a market cap of 258.4B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while AZN trades at $166.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas AZN's P/E ratio is 17.99. In terms of profitability, AMGN's ROE is +0.89%, compared to AZN's ROE of +0.22%. Regarding short-term risk, AMGN is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check AZN's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, GILD has a market cap of 185.6B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while GILD trades at $150.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas GILD's P/E ratio is -383.82. In terms of profitability, AMGN's ROE is +0.89%, compared to GILD's ROE of -0.16%. Regarding short-term risk, AMGN is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check GILD's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, NVO has a market cap of 172.3B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while NVO trades at $38.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas NVO's P/E ratio is 9.65. In terms of profitability, AMGN's ROE is +0.89%, compared to NVO's ROE of +0.59%. Regarding short-term risk, AMGN is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check NVO's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, PFE has a market cap of 163.5B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while PFE trades at $28.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas PFE's P/E ratio is 9.40. In terms of profitability, AMGN's ROE is +0.89%, compared to PFE's ROE of +0.05%. Regarding short-term risk, AMGN is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check PFE's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, BMY has a market cap of 128.5B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while BMY trades at $62.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas BMY's P/E ratio is 10.60. In terms of profitability, AMGN's ROE is +0.89%, compared to BMY's ROE of +0.47%. Regarding short-term risk, AMGN is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check BMY's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, GSK has a market cap of 99.5B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while GSK trades at $49.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas GSK's P/E ratio is 10.72. In terms of profitability, AMGN's ROE is +0.89%, compared to GSK's ROE of +0.24%. Regarding short-term risk, AMGN is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check GSK's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, SNY has a market cap of 98.7B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while SNY trades at $41.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas SNY's P/E ratio is 8.96. In terms of profitability, AMGN's ROE is +0.89%, compared to SNY's ROE of +0.06%. Regarding short-term risk, AMGN is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check SNY's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, BIIB has a market cap of 33.6B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while BIIB trades at $227.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas BIIB's P/E ratio is 14.37. In terms of profitability, AMGN's ROE is +0.89%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, AMGN is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check BIIB's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AMGN's ROE is +0.89%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AMGN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check HZNP's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, GRFS has a market cap of 6.1B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while GRFS trades at $7.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas GRFS's P/E ratio is 8.26. In terms of profitability, AMGN's ROE is +0.89%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, AMGN is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check GRFS's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while OGN trades at $13.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas OGN's P/E ratio is 4.10. In terms of profitability, AMGN's ROE is +0.89%, compared to OGN's ROE of +0.23%. Regarding short-term risk, AMGN is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check OGN's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, AMRN has a market cap of 273M. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while AMRN trades at $13.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas AMRN's P/E ratio is -132.00. In terms of profitability, AMGN's ROE is +0.89%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, AMGN is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check AMRN's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, SCLX has a market cap of 41.5M. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while SCLX trades at $4.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas SCLX's P/E ratio is -0.13. In terms of profitability, AMGN's ROE is +0.89%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, AMGN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check SCLX's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, MIRA has a market cap of 37.8M. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while MIRA trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas MIRA's P/E ratio is -0.62. In terms of profitability, AMGN's ROE is +0.89%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, AMGN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check MIRA's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, SCLXW has a market cap of 21.3M. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while SCLXW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.89%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, AMGN is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check SCLXW's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, AMGN's ROE is +0.89%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, AMGN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check BDSIW's competition here

Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMGN stands at 223.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AMGN is priced at $414.61 on the NASDAQ, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMGN currently has a P/E ratio of 18.53, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AMGN's ROE is +0.89%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AMGN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CRXT's competition here